This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.
Cardiovascular Systems Gets Approvals in Japan, Widens Suite
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.
Cardiovascular Systems Treats First Patient With Teleport
by Zacks Equity Research
Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.
Why Is Cardiovascular Systems (CSII) Up 10.8% Since Last Earnings Report?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems' (CSII) Q1 Loss Wider Than Expected
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q1.
Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and 0.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) Q1 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global
by Zacks Equity Research
Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.
Cardiovascular Systems Portfolio Strong, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.
Zacks.com featured highlights include: Cardiovascular, AMC, Osisko and Agnico Eagle
by Zacks Equity Research
Zacks.com featured highlights include: Cardiovascular, AMC, Osisko and Agnico Eagle
Why Is Cardiovascular Systems (CSII) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Toxic Stocks to Get Rid Off or Sell Short for Solid Gains
by Zacks Equity Research
Pricey toxic stocks are usually vulnerable to external shocks and loaded with a huge amount of debt.
Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data
by Zacks Equity Research
The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overpriced toxic stocks are generally susceptible to external shocks and loaded with a high level of debt.
Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.
Cardiovascular Systems (CSII) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 83.33% and 1.24%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Cardiovascular Systems (CSII) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Cardiovascular Systems Rides on New Products Amid Tight Race
by Zacks Equity Research
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.
Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet
by Zacks Equity Research
Cardiovascular Systems' (CSII) peripheral device revenues continue to gain from a consistent strength in hospital setting.
Cardiovascular Systems (CSII) Up 2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems Gains From 510K for OrbusNeich Device
by Zacks Equity Research
Cardiovascular Systems (CSII) to distribute limited editions of both 1.0-4.0mm Sapphire II PRO and 2.0-4.0mm Sapphire NC Plus non-compliant coronary balloons post the product launches in the market.
Cardiovascular Systems Portfolio Solid, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses year-over-year increase in Q2 revenues on strength in both the segments.
Cardiovascular Systems' Micro Crown Now Available in Japan
by Zacks Equity Research
Cardiovascular Systems (CSII) is positioned to gain from favorable trend in the CAD market.
Positive Market Trends Aid Cardiovascular Systems Amid Woes
by Zacks Equity Research
Cardiovascular Systems (CSII) firmly stands to gain from several favorable trends existing in the PAD and CAD market spaces.